This contact form is for your comments or questions concerning our company. Please note that the form is not to be used to report health concerns or to ask any questions, technical or medical, regarding Sanophi products.
- For patients: please contact your personal physician.
- For healthcare professionals: if you wish to report an unexpected adverse event occurred in a patient treated by one of our products, could you please use the current procedure in force in your country.
Preventing and Treating
January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.
January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes